Celldex details Phase 2 Barzolvolimab EoE data

Celldex Therapeutics filed a Form 8-K to report that, on August 19, 2025, it issued a press release with results from its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus.

Rhea-AI Filing Summary

Celldex Therapeutics filed a Form 8-K to report that, on August 19, 2025, it issued a press release with results from its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The company attached this press release as Exhibit 99.1 and incorporated it by reference, making the clinical trial outcome an official part of its public disclosures.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex Therapeutics (CLDX) disclose in this Form 8-K?

Celldex Therapeutics disclosed that it issued a press release on August 19, 2025 announcing results from its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis (EoE).

Which Celldex drug is covered in the August 19, 2025 CLDX 8-K filing?

The filing covers clinical results for Barzolvolimab from a Phase 2 study in patients with Eosinophilic Esophagitis (EoE).

Where can investors find the detailed Phase 2 Barzolvolimab EoE results for Celldex (CLDX)?

The detailed Phase 2 results are contained in the press release attached as Exhibit 99.1 to the Form 8-K and incorporated by reference.

What is the purpose of Celldex Therapeutics filing this 8-K about Barzolvolimab?

The purpose is to formally record that Celldex issued a press release announcing Phase 2 study results for Barzolvolimab in EoE, treating this communication as a reportable event.

Does this Celldex (CLDX) 8-K include financial results or major transactions?

No, this 8-K is filed under Item 8.01 Other Events and focuses on disclosure of Phase 2 clinical trial results, not financial results or major transactions.

Who signed the Celldex Therapeutics August 19, 2025 Form 8-K?

The Form 8-K was signed on behalf of Celldex Therapeutics by Sam Martin, Senior Vice President and Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/19/2025 - 04:04 PM EDT Learn about SEC filing dates

false 0000744218 0000744218 2025-08-19 2025-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

Celldex Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-15006		13-3191702
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Perryville III Building, 53 Frontage Road, Suite 220

Hampton, New Jersey 08827

(Address of Principal Executive Offices) (Zip Code)

(908) 200-7500

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.001	CLDX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On August 19, 2025, Celldex Therapeutics, Inc. issued a press release announcing results from its Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1	Press Release of Celldex Therapeutics, Inc., dated August 19, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Celldex Therapeutics, Inc.
Date: August 19, 2025	By:	/s/ Sam Martin
		Sam Martin
		Senior Vice President and Chief Financial Officer